Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Gilead Sciences (GILD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Phathom Pharmaceuticals (PHAT – Research Report) and Gilead Sciences (GILD – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Phathom Pharmaceuticals (PHAT)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Phathom Pharmaceuticals today. The company’s shares closed last Monday at $11.18.
According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of
Currently, the analyst consensus on Phathom Pharmaceuticals is a Strong Buy with an average price target of $25.83.
See today’s best-performing stocks on TipRanks >>
Gilead Sciences (GILD)
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Gilead Sciences, with a price target of $170.00. The company’s shares closed last Monday at $149.73.
According to TipRanks.com, Stringer is a 5-star analyst with an average return of
Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $155.45, which is a 4.4% upside from current levels. In a report issued on February 10, UBS also maintained a Buy rating on the stock with a $155.00 price target.
